Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BSI4
UPID:
TINF2_HUMAN
Alternative names:
TRF1-interacting nuclear protein 2
Alternative UPACC:
Q9BSI4; B3W5Q7; Q9H904; Q9UHC2
Background:
TERF1-interacting nuclear factor 2, also known as TRF1-interacting nuclear protein 2, plays a crucial role in telomere maintenance by being a component of the shelterin complex. This complex is essential for regulating telomere length and protection, ensuring chromosome ends are shielded from DNA damage surveillance mechanisms. Its involvement in shelterin complex assembly and potential role in tethering telomeres to the nuclear matrix highlight its significance in cellular longevity and genomic stability.
Therapeutic significance:
The protein's association with Dyskeratosis congenita, autosomal dominant, 3 and 5, diseases characterized by defective telomere maintenance leading to a spectrum of clinical manifestations, underscores its therapeutic potential. Targeting the pathways involving TERF1-interacting nuclear factor 2 could offer novel strategies for treating these complex disorders, emphasizing the importance of understanding its biological functions.